China Bao'an Group Co., Ltd 2025 Board of Directors Work Report In 2025, China Baoan Group Co., Ltd. (hereinafter referred to as "the Company," "the Group" or "the Middle"). Guobaoan") The board of directors strictly complies with the Company Law, Securities Law, and Shenzhen Stock Exchange Stock Listing Rules. and other laws, regulations, normative documents, and relevant provisions of the Articles of Association to earnestly fulfill the duties of the board of directors, Operate in a standardized manner and make scientific decisions, continuously improve corporate governance, and promote the company's sustained, stable, and healthy development. Effectively safeguarding the legitimate rights and interests of the company and all shareholders.
- Annual Operational Management of the Company In 2025, facing a complex and ever-changing internal and external environment and numerous challenges, the Group will focus on "strengthening and enhancing the core." Focus on business, clean up and rectify non-nuclear businesses, and plan for future business operations," responding calmly and prudently Policies were implemented to stabilize the team, operations, and funds, successfully completing the transition between old and new generations, while scientifically planning future development Seizing opportunities to plan and lay out strategies, and making beneficial attempts in industrial mergers and acquisitions, the group's overall operations have shown stability Momentum and strong resilience. The group's core business segments are high-tech and biomedicine, with operating revenue and total profits achieved double growth, including: high-tech industries saw increased demand in the new energy vehicle and energy storage markets Driven by this, focusing on its core business, guided by customer needs, and relying on "technological innovation + global layout" Driven by dual engines, it continuously consolidated the business foundation, achieving sales revenue of 18,698,371,300 yuan during the reporting period, same year a year-on-year increase of 17.68%; Total profit reached 1,390.2031 million yuan, a year-on-year increase of 18.22%; Biopharmaceutical products The industry is facing multiple factors such as macroeconomic fluctuations, deepening industry policy adjustments, channel landscape restructuring, and intensified market competition The combined impact of factors further focuses on highly competitive advantageous businesses, continuously optimizes business structure, and operates steadily. During the reporting period, sales revenue reached 3,940.9783 million yuan, a year-on-year increase of 3.87%; Total profit achieved was 69,165.57 ten thousand yuan, a year-on-year increase of 8.21%. However, non-nuclear business still faces significant operational pressure, and progress in disposing of inefficient assets is stagnant Afterwards, the intensity of cleanup and rectification still needs to be further strengthened. During the reporting period, the Group achieved total operating revenue of 23,036,277,200 yuan, an increase compared to the same period last year 13.87% ； Operating cost was 17,088,662,800 yuan, up 16.17% from the same period last year; Sales expenses 1,194.6073 million yuan, an increase of 7.19% compared to the same period last year; Administrative expenses were 1,391,046,100 yuan, unchanged from the previous year Growth of 1.79%; Financial expenses were 670.1106 million yuan, an increase of 105.41% compared to the same period last year; Belonging to the mother Net profit attributable to the company was 203.0417 million yuan, an increase of 17.62% compared to the same period last year; Belongs to the parent company 1
For others, net profit after deducting non-recurring gains and losses was -71.5965 million yuan, a decrease of 341.34% compared to the same period last year. 2. Daily Work of the Board of Directors (1) Status of Board Meetings
In 2025, the company organized six Board meetings, including procedures for convening, holding, and voting All comply with the Company Law, Articles of Association, and other relevant regulations. The specific details of the meeting are as follows: No. Session of the Meeting Date Main Proposals of the Meeting
- "China Bao'an Group Co., Ltd. 2024 Annual Report."